SCHEMBL30366269

SCHEMBL30366269

COc1cc(Br)cnc1Cl

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 4/20 0.42
CHRNA4 P43681 4/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 1/20 0.40
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CHRNB4 P30926 2/20 0.38
CHRNA3 P32297 2/20 0.38
CHRNA7 P36544 2/20 0.38
NQO2 P16083 2/20 0.36
SHMT2 P34897 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL608749 1.00 CHRNB2 (0.42) CHRNB2CHRNA4MEN1KMT2APOLB
SCHEMBL30499138 0.81 EGFR (0.33) MEN1KMT2APOLB
SCHEMBL2147358 0.81 EGFR (0.33) MEN1KMT2APOLB
SCHEMBL26170410 0.81 HTT (0.35) KMT2A
SCHEMBL189068 0.80 GRM5 (0.44) MEN1KMT2APOLBALDH1A1SMN1; SMN2
SCHEMBL29812510 0.80 PLAU (0.42) POLBALDH1A1KDM4E
SCHEMBL17593337 0.80 PLAU (0.42) POLBALDH1A1KDM4E
SCHEMBL28850186 0.79 KMT2A (0.39) MEN1KMT2APOLB
SCHEMBL30866857 0.79 MET (0.41)
SCHEMBL21512505 0.79 MET (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4405051-A1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2024-07-31 EP disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
WO-2023046806-A1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2023-03-30 WO disclosed